Navigation Links
Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
Date:4/25/2012

SAN FRANCISCO, April 25, 2012 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter ended March 31, 2012 on Wednesday, May 2, 2012, after the close of U.S.-based financial markets. Howard Robin, president and chief executive officer, will host a conference call to provide a general business update and review the first quarter results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.

The press release and a live audio-only Webcast of the conference call can be accessed through a link that is posted on the home page and Investor Relations section of the Nektar website: http://www.nektar.com. The web broadcast of the conference call will be available for replay through Saturday, June 2, 2012.

To access the conference call, follow these instructions:


Dial: (866) 203-3436 (U.S.); (617) 213-8849 (international)

Passcode: 64392378 (Nektar Therapeutics is the host)

An audio replay will also be available shortly following the call through Saturday, June 2, 2012 and can be accessed by dialing (888) 286-8010 (U.S.); or (617) 801-6888 (international) with a passcode of 29485870.

About Nektar

Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms.  Nektar has a robust R&D pipeline of potentially high-value therapeutics in oncology, pain and other therapeutic areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for naloxegol (NKTR-118), an investigational drug candidate, which is being evaluated in Phase 3 clinical studies as a once-daily, oral tablet for the treatment of opioid-induced constipation.  This agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of naloxegol and an opioid.  NKTR-181, a novel mu-opioid analgesic in development to treat chronic pain, has completed Phase 1 development and is being prepared for a Phase 2 study.  NKTR-192, a novel mu-opioid analgesic in development to treat acute pain, is in Phase 1 clinical development.  In oncology, etirinotecan pegol (NKTR-102) is being evaluated in a Phase 3 clinical study for the treatment of metastatic breast cancer and in Phase 2 studies for the treatment of ovarian and colorectal cancers.

Nektar's technology has enabled eight approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including Affymax's OMONTYS® for anemia, UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia.  Additional development-stage products that leverage Nektar's proprietary technology platform include Baxter's BAX 855, a long-acting PEGylated rFVIII program, which is in Phase 1 clinical development.

Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India.  Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

CONTACT:  Jennifer Ruddock of Nektar Therapeutics, +1-415-482-5585


'/>"/>
SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Nektar Consolidates Research at Its State-of-the-Art R&D Center Located in San Francisco at Mission Bay
2. Nektar Therapeutics Reports Fourth Quarter and Year-End 2011 Financial Results
3. Nektar Therapeutics Announces Agreement to Sell CIMZIA® and MIRCERA® Royalties to Royalty Pharma for $124 Million
4. Nektar Presents Positive Proof-of-Concept Clinical Data for Its New Opioid Molecule, NKTR-181, at American Academy of Pain Medicines 28th Annual Meeting
5. Nektar to Announce Financial Results for the Fourth Quarter and Year-End of 2011 on Wednesday, February 29, 2012, After Close of U.S.-Based Financial Markets
6. Positive Data for Nektars New Mu-Opioid Analgesic Molecule to Treat Acute Pain Highlighted at Neuroscience 2011
7. Nektar Therapeutics Reports Third Quarter 2011 Financial Results
8. Nektar to Announce Financial Results for the Third Quarter of 2011 on Wednesday, November 2, 2011, After Close of U.S.-Based Financial Markets
9. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the UBS 2011 Global Life Sciences Conference in New York City
10. Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Chronic Pain
11. Nektar Therapeutics Reports Second Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2020)... ... June 27, 2020 , ... CPAP Store USA, known for its ... other respiratory devices, is growing and expanding at a rapid rate. Today, CPAP store ... Texas - CPAP Store Dallas, located at 3920 Rosemeade Parkway, Suite 150, Dallas, Texas ...
(Date:6/25/2020)... ... June 25, 2020 , ... ... unmet needs in the field of urology, today announced that Tarek Pacha, D.O., ... Excellence. The designation recognizes that Dr. Pacha has achieved a high level of ...
(Date:6/25/2020)... , ... June 25, 2020 , ... ... Connecticut Magazine’s 2020 Top Dentist list within the Periodontics category. As specialists, this ... in New London, CT and Westerly, RI. Laser gum disease therapy, minimally invasive ...
Breaking Medicine Technology:
(Date:7/7/2020)... ... July 07, 2020 , ... Dr. Louis M. DeJoseph ... to improve their scalp health. It is now possible to receive Keravive treatments from ... to his practice, Dr. DeJoseph is able to provide clients with the best services ...
(Date:7/4/2020)... FRANCISCO, Calif. (PRWEB) , ... July 03, 2020 ... ... scientific breakthroughs are prominently featured in Biocompare’s latest content hub— Future Lab: COVID-19 ... to showcase the latest advancements, trends, news, and products within specific scientific niches. ...
(Date:7/2/2020)... ... July 02, 2020 , ... Temprian, ... of autoimmune diseases. Its lead indication is vitiligo. Vitiligo patients develop progressive ... , While vitiligo is equally prevalent in all ethnic groups, it ...
(Date:7/2/2020)... (PRWEB) , ... July 02, 2020 , ... Allegheny Health ... organization’s new Chief Medical Information Officer (CMIO), effective immediately. Dr. Lee succeeds Robert ... stay with AHN through the end of the year to help support a seamless ...
(Date:7/1/2020)... (PRWEB) , ... July 01, 2020 , ... ... cannabis and botanically-derived terpenes, has officially released its new terpene infused product ... a way for consumers to enjoy cannabis terpene profiles and flavors worldwide. , ...
Breaking Medicine News(10 mins):